5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma

Figure 5 Oncogenic role of 5’-transfer RNA halve-lysine-CTT in hepatocellular carcinoma. A: Expression of 5’-transfer RNA halve (tiRNA)-lysine (Lys)-CTT in six hepatocellular carcinoma cell lines and the normal liver cell line (QSG-7701) measured by quantitative polymerase chain reaction; B: Intracellular localization of 5’-tiRNA-Lys-CTT in MHCC97-H and Hep3B cell lines assessed by nuclear-cytoplasmic fractionation; C: Efficiency of 5’-tiRNA-Lys-CTT mimic and inhibitor in MHCC97-H and Hep3B cells evaluated by quantitative polymerase chain reaction; D: Cell viability of MHCC97-H and Hep3B cells following transfection with 5’-tiRNA-Lys-CTT mimic, mimic negative control, inhibitor, or inhibitor negative control, measured by CCK-8 assay; E: Colony formation assays to determine the effect of 5’-tiRNA-Lys-CTT on cell growth and proliferation. All the values are as mean ± SD. ^aP < 0.01; ^bP < 0.001; ^cP < 0.0001. tiRNA: Transfer RNA halve; Lys: Lysine; NC: Negative control.